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Background: The aim of the study was to evaluate the sense of smell in patients with
bronchiectasis.
Methods: Prospective controlled study was performed on 91 patients with bronchiectasis.
Bronchiectasis patients were sub-classified depending on: the presence of chronic rhino-
sinusitis, with or without nasal polyps, and the bronchiectasis ethiology. Olfactory function
was evaluated by means of the Barcelona Smell Test (BAST-24) olfactometry for detection,
identification, and forced choice for the first and fifth cranial nerve dependent odours in
comparison to a group of 120 healthy volunteers.
Results: Most patients with bronchiectasis (80.2%) satisfied EP3OS criteria of chronic rhino-
sinusitis (CRS), and 26.4% presented nasal polyps (NP). Smell detection, identification, and
forced choice tests were significantly (p < 0.001) worse in bronchiectasis patients than healthy
controls for both the 1st and 5th CN. Among subgroups, patients with CRS presented a significant
(p < 0.05) reduction in smell detection compared to both healthy controls and patients without
CRS. Patients with both CRS and NP presented a significant (p < 0.01) reduction in both smell
detection and forced choice compared to patients with CRS and without NP. Patients with bron-
chiectasis and primary humoral immunodeficiency had a poorer smell detection (p< 0.001) and
forced choice (p < 0.001) compared with post-infective and idiopathic bronchiectasis patients.nit & Smell Clinic, Department of Otorhinolaryngology e Head & Neck Surgery, Hospital Clı´nic i
l 170, Barcelona 08036, Spain. Tel.: þ34 932 279 872; fax: þ34 932 275 454.
com (J.M. Guilemany).
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Olfaction in bronchiectasis 45Conclusions: Patientswith bronchiectasis have amoderate loss of smell with a higher impairment
in patients with CRS, beingmaximal in patients with NP. Patients with immunodeficiency bronchi-
ectasis showed high prevalence of CRS, and therefore marked impairment on the sense of smell.
The mechanism could be explained through a mixed ethiology (obstruction/inflammation).
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Bronchiectasis is a chronic bronchial disease with a structural
derangement of the bronchial wall, with permanent and
irreversible destruction and dilatation, retained secretions,
and recurrent infections which cause inflammation, obstruc-
tion, damageof the lower airway, significant impact on health
care, and impairment of the quality of life (QoL).1e3 Bron-
chiectasis is a consequence of a variety of different diseases
whereby infection and excessive mucous production appear
to be themost important contributory factors. Althoughmore
than 50% of bronchiectasis cases are still considered idio-
pathic, the study of contributing potential causes may have
important implications for the management of the disease.4
Supporting the “united airways” concept, we’ve demon-
strated that almost three in four patients with BQ (77%) pre-
sented criteria for chronic rhinosinusitis (CRS), and one in four
patients had nasal polyps (NP) at nasal endoscopy (25%).5 Our
findings also suggest that patients with bronchiectasis should
always be evaluated for CRS and NP, while patients with CRS
and NP should also be assessed for lower airway diseases,
including bronchiectasis.5 In addition, patients with bronchi-
ectasis and CRS have worse pulmonary function and more
bronchiectasis extension on HRCT scan.5 Also the presence
of CRS has a negative impact on the QoL of patients with
bronchiectasis6,7 and is associated to an increased bronchial
colonisation with potentially pathological microbes.8
Alterations in olfaction in patients with bronchiectasis
with or without sinonasal pathology have not yet been
evaluated using subjective olfactometry. Several odour-
identification tests have been developed for clinical use in
different countries and cultures. However, due to the fact
that the nature of odour identification is closely related to
familiar and cultural aromatic items, this usually limits the
use of olfactory tests to the country or region where they
have been developed and validated. So far, the Barcelona
Smell Test-24 (BAST-24),9 a smell test validated for the
Spanish and Mediterranean population, has been used to
evaluate the sense of smell in the healthy Spanish pop-
ulation,9 and the loss of smell in persistent allergic rhinitis10
patients, showing a link between the magnitude of smell
disorders and the severity of allergic rhinitis.
The aim of this study was to assess the sense of smell in
patients with bronchiectasis depending on: 1) the existence
ofCRSwith/withoutNP,and2) theethiologyofbronchiectasis.
Materials and methods
Study population
Patients (nZ 91) with idiopathic, post-infective, or primary
humoral immunodeficiency (PHI) bronchiectasis in a stablephase of their illness were included in this prospective
controlled study fromMarch 2007 to February 2009. Seventy-
three patients fulfilled EP3OS criteria11 for CRS (80.2%), and
twenty-four had NP (26.4%).9 The control group consisted of
120 healthy, community volunteers of middle socioeconomic
class from Barcelona in the same area as recruited patients.
Individuals with neurodegenerative disorders such as
Alzheimer and Parkinson diseases, and nasal disorders such
as nasal polyps, chronic rhinosinusitis, or allergic rhinitis
were excluded from the study. All olfactometries in healthy
controls were performed before the cases.9
Design
As reported in the previous study,5 the diagnosis of bron-
chiectasis was performed on the basis of characteristic
clinical symptoms and chest-CT scanning (Siemens Emotion
Duo Two-slice 5 mm with high resolution slices 1 mm for
pulmonary parenchyma). Stability of the bronchiectasis
condition was assessed by a complete clinical evaluation,
forced spirometry and, where necessary, chest radiology.
Stable bronchiectasis condition was defined as the absence
of fever, no impairment of airflow limitation, no increase in
sputum overproduction or change in the macroscopic
characteristics (purulence), and no increase in chronic
cough. In summary, stable bronchiectasis showed no
increase in respiratory symptoms or modifications in the
treatment throughout the previous 6 weeks. Post-infective
bronchiectasis was diagnosed when the patient reported
a history of symptoms appearing immediately after a severe
infection, such as pneumonia, tuberculosis or whooping
cough. All patients were evaluated for serum immuno-
globulins (Ig), IgG, IgA, IgM, and IgG subclasses (1e4) to
discard PHI. Idiopathic bronchiectasis was diagnosed when
known causes of bronchiectasis were ruled out. The Ethics
Committee of our institution approved the study and signed
informed consent was obtained from all patients.
Exclusion criteria were: hospitalization in the previous
2 months, use of antibiotics in the previous 4 weeks, pseu-
domona colonisation, or presence of a serious concomitant
illness.
To characterise the involvement of upper airway disease in
patients with bronchiectasis, the following diagnostic
outcomes and tools were used in the study: nasal symptom
score, nasal endoscopy, sinonasal CT-scan (Siemens Somaton
P4 Unislice 3 mm). Nasal congestion/obstruction/blockage,
reduction or loss of the sense of smell, anterior rhinorrhea,
post-nasal drip, facial pain/pressure, itching, and sneezing
was scored using a Likert classification (0e3). Polyp size was
scored from0 to 3 for each nasal cavity using nasal endoscopy,
following Lildholdt’s classification.12 A radiologist blindly
staged sinus occupation for each patient, using CT scanning
and the LundeMacKay score system (0e24).13 Nasal function
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46 J.M. Guilemany et al.was measured by rhinomanometry and acoustic rhinometry.
Nasal and bronchial inflammation was evaluated by nasal and
exhaled nitric oxide (NO), respectively. These results have
already been published in a previous manuscript.5
Olfactometry
After a 4-week washout period for oral and intranasal
steroids, all patients were analysed for smell disorders by
means of BAST-24 olfactometry.9,10 Patients were single
blinded to 20 odours for the 1st cranial nerve and 4 odours
for the 5th cranial nerve. Briefly, as previously described,
the smell test was performed in a quiet, noise isolated,
well-ventilated room, with controlled humidity (40e70%)
and temperature (21e23 C). Neither the examiner nor the
patients and controls were allowed to apply any perfumes,
lotions, or creams beforehand. All the odorants were
located in hermetic glass jars. Once opened, the odorant
jars were randomly presented at 1 cm from the nose with
no contact between the explorer’s finger and patient’s
face. Patients were studied for the different smell char-
acteristics: detection, identification, and forced choice
(4 options).
Statistical analysis
Statistics were performed using SPSS for Windows (SPSS 15.0,
Chicago, IL, USA). All analyses were performed using two-
tailed test significance at the p < 0.05 level. The data are
presented as mean  standard error of the mean (SEM).
Comparisons for differences in olfactory detection, identifi-
cation, and forced choice between groups were performed
using Student’s t test. Pearson correlation coefficients were
used to examine the association between BAST-24 outcomes
and nasal symptoms, nasal patency, sinonasal CT-scan,
pulmonary HRCT scan, and nasal/exhaled NO.
Results
Demographic data
Among patients with bronchiectasis (n Z 91); 59.3%
(n Z 54) were classified as post-infective bronchiectasis,
30.8% (n Z 28) as idiopathic bronchiectasis, while 9.9%
(n Z 9) as bronchiectasis due to PHI. The mean age was
54.7  1.6 years (ranging from 18 to 82 years), predomi-
nantly women (68.1%), 5.5% were current smokers and
23.1% were ex-smokers. The mean age at bronchiectasis
diagnosis was 40.1  2.1 years. Patients with CRS (38.4  2
years), mainly with NP (36.2  4.5 years) were diagnosed
with bronchiectasis earlier than patients with no sinonasal
pathology (46  4 years). Patients with CRS, 69.8% of them
being female, had a significant higher female ratio (2.3:1),
this ratio was even higher in patients with CRS without NP
(5.1:1), compared to patients with no CRS (1:1) or patients
with CRS with NP (1:1). Most of BQ patients (80.2%) had
CRS, while 26.4% had NP (Table 1). Interestingly, all
patients with PHI bronchiectasis fulfilled EP3OS criteria11
for CRS and 55.5% had NP at nasal endoscopy. No signifi-
cant differences existed regarding the presence of CRS
depending on smoking history.
B0
20
40
60
80
100
Healthy 
controls
Total BQ No CRS CRS CRS-NP CRS+NP
IDENTIFICATION
p<0.001
p<0.001
p<0.001
p<0.05
P<0.001
NS NS 
A
0
20
40
60
80
100
Healthy controls Total BQ No CRS CRS CRS-NP CRS+NP
DETECTION
p<0.01 p<0.05 p<0.01 
p<0.01
p<0.05
p<0.01
C
20
40
60
80
100
FORCED CHOICE
p<0.001
p<0.001
p<0.001
p<0.001
p<0.001
p<0.01
Olfaction in bronchiectasis 47Olfactory function
For the 1st cranial nerve (CN) odours, patients with bron-
chiectasis had worse scores (p < 0.001) in smell detection,
identification, and forced choice compared to healthy
controls. Curiously, patients with bronchiectasis without
CRS had a poorer smell identification and forced choice
(p < 0.001) compared to healthy controls. Patients with
EP3OS criteria of CRS showed worse scores in smell detec-
tion (p < 0.05), but not in identification and forced choice
than patients without CRS. In addition, patients with CRS
with NP showed worse scores in smell detection (p < 0.05),
and forced choice (p < 0.05) but not in identification com-
pared to patients with CRS without NP (Fig. 1).
There was an inverse correlation between the symptom
“loss of smell” score and smell identification (R: 0.500;
p < 0.001) and forced choice (R: 0.400; p < 0.001) mea-
sured by BAST-24, and the “loss of smell” score and the
anterior (R: 0.400; p < 0.001) and posterior (R: 0.400;
p < 0.001) ethmoid sinus occupation by sinonasal CT-scan.
The smell identification (R: 0.400; p < 0.001) and forced
choice (R: 0.300; p < 0.05) measured by BAST-24 had a
direct correlation with the volume (0e6 cm) by acoustic
rhinometry. Also the smell detection (R: 0.300; p < 0.05)
and identification (R: 0.350; p < 0.05) by BAST-24 corre-
lated with the level of nasal NO.
Patients with bronchiectasis and PHI had a poorer smell
detection (DT: 69.4  15%; p < 0.001) and forced choice
(FC: 36.6  9.8%; p < 0.001) compared with post-infective
(DT: 97.1  1.7%, FC: 59.4  2.5%) and idiopathic (DT:
92.3  4%, FC: 58.7  5%) bronchiectasis (Fig. 2). This find-
ing could be due to a higher prevalence of CRS with or
without NP. Compared to patients with post-infective
bronchiectasis, patients with PHI also had a higher “loss
of smell” score (0.54  0.1 vs. 1.5  0.5; p < 0.05) and
sinonasal CT-scan score (6.2  0.5 vs. 9.8  1.4; p < 0.05).
For the 5th CN, patients with bronchiectasis also had
poorer scores for smell detection, identification, and
forced choice compared to healthy controls (Table 2).0
Healthy 
controls
Total BQ No CRS CRS CRS-NP CRS+NP
Figure 1 Olfactory function measurements by using BAST-24
for both the 1st cranial nerve on bronchiectasis patients with/
without CRS and with/without NP and healthy controls for:
A: smell detection, B: identification, and C: forced choice.
Unpaired Student’s t test was used.Discussion
This is the first study to describe in-depth the characteristics
of olfactory dysfunction in patients affected by bronchiec-
tasis. The major findings of the present study were: 1) there
is a clear impairment of smell dysfunction in the detection,
identification, and forced choice in bronchiectasis patients,
compared to healthy controls; 2) the loss of smell detection
and identification is particularly present in CRS patients,
being higher in NP patients and in PHI bronchiectasis;
3) patients with BQ without CRS have normal values on smell
detection but not on identification, and forced choice. In
conclusion, these results strongly support the notion that
suffering from bronchiectasis has a moderate impact on the
sense of smell.
Among the most prevalent causes of smell disorders, we
may include viral upper respiratory tract infection,14,15 and
chronic sinonasal inflammatory diseases such as allergic
rhinitis, CRS and NP. Patients with persistent allergic
rhinitis (PER) have a moderate loss of smell with a higher
impairment seen in those with self-reported hyposmia andmoderate-to-severe PER.10 Patients with CRS with NP have
an impaired sense of smell, while asthmatics and especially
those with persistent asthma have an increased impact on
the loss of smell. The loss of smell may be used as a clinical
tool to identify both NP and asthma severity.16
Previous reports5e7 from our group have demonstrated
that 77% of patients with post-infective/idiopathic bron-
chiectasis satisfied the EP3OS criteria11 for CRS while
moderate nasal polyps were found in 25% of patients at
endoscopy. Nasal NO was significantly lower in patients with
nasal polyposis than in those without it, and inversely
correlated with the ostiomeatal complex occupancy. In the
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IDENTIFICATION
p<0.01 NS
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20
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80
100
Total ID PI PHI
DETECTION 
p<0.001
p<0.05
p<0.05
C
0
20
40
60
80
100
Total ID PI PHI
FORCED CHOICE
p<0.01
p<0.05
p<0.05
Figure 2 Olfactory function measurements by using BAST-24
for both the 1st cranial nerve depending on bronchiectasis
ethiology (ID: idiopathic, PI: post-infective, PHI: immunodefi-
ciency) for: A: detection, B: identification, and C: forced choice.
Unpaired Student’s t test was used.
Table 2 BAST-24 olfactometry outcomes in bronchiectasis pati
with or without NP for the fifth cranial nerve.
Healthy
controls
N Z 120
Bronchiectasis (BQ)
Total
N Z 91
No C
N Z
Smell detection (%) 98.3  0.6 75.8  2.3*** 69.4
Smell identification (%) 62.7  2.6 36  3*** 32
Smell forced choice (%) 46.9  2.4 31.9  2.6*** 33.3
BQ, bronchiectasis; CRS, chronic rhinosinusitis; NP, nasal polyposis; S
Unpaired Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001, compa
48 J.M. Guilemany et al.chest HRCT scan, patients with CRS showed higher extension
of bronchiectasis than patients without CRS. Bronchiectasis
has been associatedwith loss of smell particularly in patients
with CRS and mainly in those with NP. The presence of this
olfactory loss seems to be associated with the presence of
severe CRS in patients with bronchiectasis. In addition, the
presence of CRS in patients with bronchiectasis is related to
a higher impact on QoL,6,7 a higher prevalence of potentially
pathogenic microbial colonisation,8 and a greater extension
of bronchiectasis.5 A potential limitation when assessing
olfactory function bias could be possible, if patients
considered loss of smell being causally related to their
disease. This could lead some patients to over/understate
their symptoms. Two potential causesmay be involved in the
pathogenesis of olfactory dysfunction in bronchiectasis:
obstruction and inflammation. Furthermore, the present
study has demonstrated that there is a close relationship
between olfactory dysfunction (BAST-24), nasal obstruction
(acoustic rhinometry), and nasal inflammatory changes
(nNO). These results suggest that olfactory disorders in BQ
patients may have a mixed ethiology in which the main
factors responsible are nasal obstruction and inflammation.
Classically, cystic fibrosis, primary ciliary dyskinesia, and
immunodeficiency bronchiectasis were more related to
a higher prevalence of CRS.17 In this study, patients with
PHI had a higher loss of smell, both by Likert scale and
BAST-24 as well as a higher sinonasal CT-scan occupation,
a higher bronchiectasis extension, and a tendency to poorer
lung function.
No studies had previously investigated the sense of smell
in patients with bronchiectasis by olfactometry. This is the
first study to show a moderate impact of bronchiectasis on
the sense of smell with a relationship between the severity
of CRS and the loss of smell. It is also the first to show
findings that suggest a mixed ethiology (obstruction/
inflammation) as an explanation for these smell disorders.
Thus, a simple question to patients with bronchiectasis
about their sense of smell may be a reasonable guide in
defining the potential existence of CRS with/without nasal
polyps in addition to defining patients with a higher severity
of bronchiectasis.
In summary, CRS without or with nasal polyps, is the main
cause of a partial or total loss of smell in a patient with
bronchiectasis. The sinonasal CT-scan and the nasal symp-
toms will give us the diagnosis of CRS but to identify the
presence of nasal polyps, nasal endoscopy is mandatory.
In the clinical practice, an important number of patientswith
asthma or bronchiectasis are never diagnosed of theirents and healthy controls depending on the existence of CRS
RS
18
With CRS
N Z 73
CRS-NP
N Z 49
CRS þ NP
N Z 24
 6.5*** 77.4  2.4*** 79.1  2.4*** 74  5.3***
 7.7*** 37  3.2*** 37.7  4*** 35.4  5.8***
 5.3* 31.5  3*** 32.6  3.7** 29.1  4.9**
EM, standard error of the mean.
red to healthy controls.
Olfaction in bronchiectasis 49associated sinonasal inflammatory disease. Thus, an alert
symptom like “the loss of smell” may help respiratory
physicians to refer the patients to an ENT specialist for
further diagnose and management of CRS. This could also
help respiratory physicians to prevent bronchiectasis exac-
erbations. Also, it is of essential importance to create
multidisciplinary units (with the collaboration of respiratory
physicians, allergologists, and ENT specialists) to improve
the global management, care and follow-up of these
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